



TABLE OF CONTENTS

AUTHENTICITY STATEMENT	i
ACKNOWLEDGEMENT	ii
LIST OF FIGURES.....	vi
LIST OF TABLES.....	viii
LIST OF ABBREVIATION.....	ix
ABSTRACT.....	xii
ABSTRAK.....	xiii
CHAPTER I INTRODUCTION.....	xv
A. Background	xv
B. Problem Formulation.....	xvii
C. Research Objective.....	xvii
D. Study Authenticity.....	18
E. Research Benefit.....	24
CHAPTER II LITERATURE REVIEW	26
A. Theoretical Background	26
1. Definition	26
2. Epidemiology.....	26
3. Etiopathogenesis.....	28
4. Risk Factors	31
5. Clinical Manifestations.....	31
6. Diagnosis.....	41
7. Classification Criteria	42
8. Laboratory Examination	49
9. Therapy	49
10. Remission.....	55
11. Prognosis.....	58
B. Theoretical Framework.....	59
C. Conceptual Framework.....	60
CHAPTER III RESEARCH METHODOLOGY	61
A. Study Design	61
B. Time and Study Setting.....	61



C. Population and Subject	61
D. Study Variables	61
E. Operational Definition	62
F. Study Materials and Instruments	66
G. Study Procedure	66
I. Study Flow	68
J. Ethical Considerations	69
CHAPTER IV RESULT AND DISCUSSION.....	70
A. General Description of Study Sample	70
B. Result and Discussion.....	70
1. Demographic Data	72
1.2. Sex.....	74
1.3. Age At Diagnosis	77
1.4. Nutritional Status	80
1.5. History of SLE in Family	83
1.6. Onset from Complaints to Diagnosis of SLE	85
1.7. Patients' Status	87
2.1. Initial Manifestation and Scoring of ACR-1997 Criteria.....	91
2.2. Therapies Administered to the Patients.....	95
2.3. Final Diagnosis	99
3. Laboratory Data	102
3.1. Laboratory Parameters	102
B. Research Limitations	109
CHAPTER V CONCLUSION AND SUGGESTION	110
A. Conclusion.....	110
B. Suggestion	111
REFERENCES.....	112



LIST OF FIGURES

Figure 1. 2019 EULAR/ACR Criteria	48
Figure 2. Protocol treatment for non-renal SLE according to EULAR recommendations (Fanouriakis et al., 2023).....	50
Figure 3. Protocol treatment for Lupus Nephritis according to EULAR recommendations (Fanouriakis et al., 2023).....	50
Figure 4. SLEDAI-2K Form	57
Figure 5. Theoretical Framework.....	59
Figure 6. Conceptual Framework.....	60
Figure 7. Research Flow	68
Figure 8. Research Flow	71
Figure 9.1. Number of Pediatric Patients Diagnosed with SLE in RSUP Dr. Sardjito Yogyakarta from 2021 to 2023	73
Figure 10.1. Column Charts for Female and Male Sex of Pediatric SLE patients	74
Figure 10.2. Pie Charts for Female and Male Sex of Pediatric SLE patients	75
Figure 11.1. Column Charts for Age at Diagnosis of Pediatric SLE Patients.....	77
Figure 11.2. Pie Charts for Age at Diagnosis of Pediatric SLE Patients.....	78
Figure 12.1. Column Charts for Nutritional Status of Pediatric SLE Patients Based on Body Mass Index (BMI)	80
Figure 13.1. Column Charts for Family History of SLE in pSLE Patients.....	83
Figure 13.2. Pie Charts for Family History of SLE in pSLE Patients	83
Figure 14.1. Column Chart for Onset from Complaint to Diagnosis in pSLE Patients	85
Figure 15.1. Column Chart for pSLE Patients' Status per December 2023.....	88
Figure 15.2. Pie Chart for pSLE Patients' Status per December 2023	88



Figure 15.3. Bar Charts for Cause of Death in pSLE Patients	89
Figure 16.1. Column Chart for Initial Complaints from Patients	91
Figure 16.2. Pie Chart for Initial Complaints from Patients	92
Figure 16.3. Column Chart for Manifestations Based on ACR-1997 Criteria.....	93
Figure 16.4. Pie Chart for Manifestations Based on ACR-1997 Criteria.....	93
Figure 17.1. Bar Chart for Therapies Administered to pSLE Patients.....	96
Figure 18.1. Bar Chart for Final Diagnosis of pSLE Patients.....	99
Figure 18.2. Pie Chart for Final Diagnosis of pSLE Patients	100
Figure 18.3. Column Chart for Final Diagnosis of pSLE Patients	100
Figure 19.1. Pie Chart for ANA Test Result in pSLE Patients.....	103
Figure 19.2. Pie Chart for Anti-dsDNA Test Result in pSLE Patients.....	103
Figure 19.3. Pie Chart for Anti-Sm Test Result in pSLE Patients	104
Figure 19.4. Pie Chart for C3 and C4 Level in pSLE Patients	104
Figure 19.5. Pie Chart for Direct Coombs Test Result in pSLE Patients.....	105



LIST OF TABLES

Table 1. Study Authenticity	18
Table 2. The 1997 revised criteria for classification of systemic lupus erythematosus*	42
Table 3. SLICC-2012 for diagnosis of SLE	45
Table 4. List of Operational Definition	62
Table 5. Patient Demographic Data	72
Table 6. Therapies Administered to pSLE Patients in RSUP Dr. Sardjito	95
Table 7. Laboratory Examination Performed in pSLE Patients and the Result ..	102